Annals of Oncology 14:511-519, 2003
© 2003 European Society for Medical Oncology
Review Article |
Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes
1 Institute for Health Services Research and Policy Studies, Northwestern University, Evanston, IL; 2 Univeristy of California Los Angeles School of Medicine, Los Angeles, CA, USA
Received 6 May 2002; revised 23 December 2002; accepted 15 January 2003
Abstract
Background:
Anemia occurs frequently in patients with cancer and is associated with impaired health-related quality of life (HRQOL). Treatment of anemia results in significant improvements in energy, activity and overall HRQOL, particularly among patients with mild-to-moderate anemia. Importantly, studies have indicated that anemia may have a negative impact on the success of radiotherapy, reducing survival and locoregional control. Recent preclinical and preliminary clinical data have also suggested that anemia may be associated with poorer outcomes following chemotherapy or surgery.
Materials and methods:
Data for review were identified and selected from searches of the literature published from January 1990 through to October 2002 using Medline®, and searches of proceedings from key international oncology and hematology meetings.
Results:
A wealth of data indicate that treatment of anemia improves HRQOL in patients with cancer. Prospective studies exploring survival and/or treatment outcomes in anemic cancer patients are currently in their early stages, preventing any firm conclusions from being drawn, although they do indicate a benefit in treating anemia.
Conclusions:
Recent studies support the use of erythropoietic agents in anemic cancer patients as a means of raising their hemoglobin levels and consequently improving their HRQOL. Randomized, controlled trials are needed to determine whether treating anemia with erythropoietic agents will improve other outcomes following therapy.
Key words: anemia, cancer, darbepoetin 
, health-related quality of life, recombinant human erythropoietin, survival
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Pedrazzoli, A. Farris, S. Del Prete, F. Del Gaizo, D. Ferrari, C. Bianchessi, G. Colucci, A. Desogus, T. Gamucci, A. Pappalardo, et al. Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa J. Clin. Oncol., April 1, 2008; 26(10): 1619 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Radbruch, F. Strasser, F. Elsner, J. F. Goncalves, J. Loge, S. Kaasa, F. Nauck, P. Stone, and the Research Steering Committee of the European As Fatigue in palliative care patients -- an EAPC approach Palliative Medicine, January 1, 2008; 22(1): 13 - 32. [Abstract] [PDF]
|
|
|
|
 |
|
 R. J. Muller and D. Baribeault Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia Am. J. Health Syst. Pharm., December 15, 2007; 64(24): 2547 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Hahn, D. Cella, O. Chassany, D. L. Fairclough, G. Y. Wong, R. D. Hays, and Clinical Significance Consensus Meeting Group Precision of Health-Related Quality-of-Life Data Compared With Other Clinical Measures Mayo Clin. Proc., October 1, 2007; 82(10): 1244 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Bellati, M Pernice, N Manci, I Palaia, F Tomao, C Marchetti, M. Zullo, L Muzii, R Angioli, and P. B. Panici Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors Ann. Onc., April 1, 2007; 18(4): 722 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Reeder Anemia in cancer and critical care patients: Pharmacoeconomic considerations Am. J. Health Syst. Pharm., February 1, 2007; 64(3_Supplement_2): S22 - S27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cremieux, F. Vekeman, and P. Lefebvre Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application Journal of Oncology Pharmacy Practice, September 1, 2006; 12(3): 165 - 178. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-L. Canon, J. Vansteenkiste, G. Bodoky, M. V. Mateos, L. Bastit, I. Ferreira, G. Rossi, and R. G. Amado Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst, February 15, 2006; 98(4): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Steel, D. T. Eton, D. Cella, M. C. Olek, and B. I. Carr Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma Ann. Onc., February 1, 2006; 17(2): 304 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stasi, E. Abruzzese, G. Lanzetta, E. Terzoli, and S. Amadori Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes Ann. Onc., December 1, 2005; 16(12): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Waltzman, C. Croot, G. R. Justice, M. R. Fesen, V. Charu, and D. Williams Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 {micro}g Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy Oncologist, September 1, 2005; 10(8): 642 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Weiss and L. T. Goodnough Anemia of Chronic Disease N. Engl. J. Med., March 10, 2005; 352(10): 1011 - 1023. [Full Text] [PDF]
|
|
|
|
|
|
S. Tanneberger, G. Melilli, E. Strocchi, C. Frenquelli, and Q. F. Pannuti Use of red blood cell transfusion in palliative care services: is it still up to date or is cancer-related anaemia controlled better with erythropoietic agents? Ann. Onc., May 1, 2004; 15(5): 839 - 840. [Full Text] [PDF]
|
|
|
|
 |
|
 Epoetins and {blacktriangledown}darbepoetin alfa in malignant disease DTB, March 1, 2004; 42(3): 21 - 24. [Abstract] [Full Text] [PDF]
|
|